1. Insulin glargine compared with premixed insulin for management of insulin-naïve type 2 diabetes patients uncontrolled on oral antidiabetic drugs: the open-label, randomized GALAPAGOS study 
Pablo Aschner, Bipin Sethi, Fernando Gomez-Peralta, Wolfgang Landgraf, Virginie Loizeau, Marie-Paule Dain, Valerie Pilorget, Abdurrahman Comlekci 
Journal of Diabetes and Its Complications 
Volume 29, Issue 6, Pages (August 2015)
DOI: /j.jdiacomp
Copyright © 2015 The Authors Terms and Conditions

2. Fig. 1
Seven-point BG profile of overall groups at baseline and study end.
Abbreviation: ETD, end of treatment difference; EOT, end of treatment; GLA, glargine; GLU, glulisine; PRE, premixed insulin.
Journal of Diabetes and Its Complications  , DOI: ( /j.jdiacomp )
Copyright © 2015 The Authors Terms and Conditions

3. Fig. 2
Cumulative rates of overall (A, B) and nocturnal (C, D) symptomatic hypoglycemia confirmed with BG ≤3.1 (A, C) or BG ≤3.9mmol/L (B, D): safety population. Abbreviations: BG, blood glucose; GLA, glargine; GLU, glulisine; PRE, premixed insulin; RR, relative risk.
Journal of Diabetes and Its Complications  , DOI: ( /j.jdiacomp )
Copyright © 2015 The Authors Terms and Conditions

4. Fig. 3
Estimated rates of symptomatic hypoglycemia versus HbA1c at study end: overall (A, B) and nocturnal (C, D) symptomatic hypoglycemia confirmed by BG ≤3.1mmol/L (A, C) or BG ≤3.9mmol/L (B, D). Abbreviations: BG, blood glucose; GLA, glargine; PRE, premixed insulin.
Journal of Diabetes and Its Complications  , DOI: ( /j.jdiacomp )
Copyright © 2015 The Authors Terms and Conditions